Cargando…
Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells
Skeletal muscle has high energy requirement and alterations in metabolism are associated with pathological conditions causing muscle wasting and impaired regeneration. Congenital muscular dystrophy type 1A (MDC1A) is a severe muscle disorder caused by mutations in the LAMA2 gene. Leigh syndrome (LS)...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377256/ https://www.ncbi.nlm.nih.gov/pubmed/28367954 http://dx.doi.org/10.1038/srep45272 |
_version_ | 1782519277854654464 |
---|---|
author | Fontes-Oliveira, Cibely C. Steinz, Maarten Schneiderat, Peter Mulder, Hindrik Durbeej, Madeleine |
author_facet | Fontes-Oliveira, Cibely C. Steinz, Maarten Schneiderat, Peter Mulder, Hindrik Durbeej, Madeleine |
author_sort | Fontes-Oliveira, Cibely C. |
collection | PubMed |
description | Skeletal muscle has high energy requirement and alterations in metabolism are associated with pathological conditions causing muscle wasting and impaired regeneration. Congenital muscular dystrophy type 1A (MDC1A) is a severe muscle disorder caused by mutations in the LAMA2 gene. Leigh syndrome (LS) is a neurometabolic disease caused by mutations in genes related to mitochondrial function. Skeletal muscle is severely affected in both diseases and a common feature is muscle weakness that leads to hypotonia and respiratory problems. Here, we have investigated the bioenergetic profile in myogenic cells from MDC1A and LS patients. We found dysregulated expression of genes related to energy production, apoptosis and proteasome in myoblasts and myotubes. Moreover, impaired mitochondrial function and a compensatory upregulation of glycolysis were observed when monitored in real-time. Also, alterations in cell cycle populations in myoblasts and enhanced caspase-3 activity in myotubes were observed. Thus, we have for the first time demonstrated an impairment of the bioenergetic status in human MDC1A and LS muscle cells, which could contribute to cell cycle disturbance and increased apoptosis. Our findings suggest that skeletal muscle metabolism might be a promising pharmacological target in order to improve muscle function, energy efficiency and tissue maintenance of MDC1A and LS patients. |
format | Online Article Text |
id | pubmed-5377256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53772562017-04-10 Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells Fontes-Oliveira, Cibely C. Steinz, Maarten Schneiderat, Peter Mulder, Hindrik Durbeej, Madeleine Sci Rep Article Skeletal muscle has high energy requirement and alterations in metabolism are associated with pathological conditions causing muscle wasting and impaired regeneration. Congenital muscular dystrophy type 1A (MDC1A) is a severe muscle disorder caused by mutations in the LAMA2 gene. Leigh syndrome (LS) is a neurometabolic disease caused by mutations in genes related to mitochondrial function. Skeletal muscle is severely affected in both diseases and a common feature is muscle weakness that leads to hypotonia and respiratory problems. Here, we have investigated the bioenergetic profile in myogenic cells from MDC1A and LS patients. We found dysregulated expression of genes related to energy production, apoptosis and proteasome in myoblasts and myotubes. Moreover, impaired mitochondrial function and a compensatory upregulation of glycolysis were observed when monitored in real-time. Also, alterations in cell cycle populations in myoblasts and enhanced caspase-3 activity in myotubes were observed. Thus, we have for the first time demonstrated an impairment of the bioenergetic status in human MDC1A and LS muscle cells, which could contribute to cell cycle disturbance and increased apoptosis. Our findings suggest that skeletal muscle metabolism might be a promising pharmacological target in order to improve muscle function, energy efficiency and tissue maintenance of MDC1A and LS patients. Nature Publishing Group 2017-04-03 /pmc/articles/PMC5377256/ /pubmed/28367954 http://dx.doi.org/10.1038/srep45272 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Fontes-Oliveira, Cibely C. Steinz, Maarten Schneiderat, Peter Mulder, Hindrik Durbeej, Madeleine Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
title | Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
title_full | Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
title_fullStr | Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
title_full_unstemmed | Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
title_short | Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells |
title_sort | bioenergetic impairment in congenital muscular dystrophy type 1a and leigh syndrome muscle cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377256/ https://www.ncbi.nlm.nih.gov/pubmed/28367954 http://dx.doi.org/10.1038/srep45272 |
work_keys_str_mv | AT fontesoliveiracibelyc bioenergeticimpairmentincongenitalmusculardystrophytype1aandleighsyndromemusclecells AT steinzmaarten bioenergeticimpairmentincongenitalmusculardystrophytype1aandleighsyndromemusclecells AT schneideratpeter bioenergeticimpairmentincongenitalmusculardystrophytype1aandleighsyndromemusclecells AT mulderhindrik bioenergeticimpairmentincongenitalmusculardystrophytype1aandleighsyndromemusclecells AT durbeejmadeleine bioenergeticimpairmentincongenitalmusculardystrophytype1aandleighsyndromemusclecells |